223 related articles for article (PubMed ID: 17286389)
1. Employing mutants to study thrombin residues responsible for factor XIII activation peptide recognition: a kinetic study.
Isetti G; Maurer MC
Biochemistry; 2007 Mar; 46(9):2444-52. PubMed ID: 17286389
[TBL] [Abstract][Full Text] [Related]
2. Thrombin activity is unaltered by N-terminal truncation of factor XIII activation peptides.
Isetti G; Maurer MC
Biochemistry; 2004 Apr; 43(14):4150-9. PubMed ID: 15065858
[TBL] [Abstract][Full Text] [Related]
3. Probing thrombin's ability to accommodate a V34F substitution within the factor XIII activation peptide segment (28-41).
Isetti G; Maurer MC
J Pept Res; 2004 Mar; 63(3):241-52. PubMed ID: 15049836
[TBL] [Abstract][Full Text] [Related]
4. Design of Factor XIII V34X activation peptides to control ability to interact with thrombin mutants.
Jadhav MA; Lucas RC; Goldsberry WN; Maurer MC
Biochim Biophys Acta; 2011 Dec; 1814(12):1955-63. PubMed ID: 21798378
[TBL] [Abstract][Full Text] [Related]
5. Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture.
Jadhav MA; Goldsberry WN; Zink SE; Lamb KN; Simmons KE; Riposo CM; Anokhin BA; Maurer MC
Biochim Biophys Acta Proteins Proteom; 2017 Oct; 1865(10):1246-1254. PubMed ID: 28687225
[TBL] [Abstract][Full Text] [Related]
6. Thrombin hydrolysis of V29F and V34L mutants of factor XIII (28-41) reveals roles of the P(9) and P(4) positions in factor XIII activation.
Trumbo TA; Maurer MC
Biochemistry; 2002 Feb; 41(8):2859-68. PubMed ID: 11851434
[TBL] [Abstract][Full Text] [Related]
7. Coagulation factor XIII variants with altered thrombin activation rates.
Andersen MD; Kjalke M; Bang S; Lautrup-Larsen I; Becker P; Andersen AS; Olsen OH; Stennicke HR
Biol Chem; 2009 Dec; 390(12):1279-83. PubMed ID: 19804366
[TBL] [Abstract][Full Text] [Related]
8. Cleavage of factor XIII by human neutrophil elastase results in a novel active truncated form of factor XIII A subunit.
Bagoly Z; Fazakas F; Komáromi I; Haramura G; Tóth E; Muszbek L
Thromb Haemost; 2008 Apr; 99(4):668-74. PubMed ID: 18392324
[TBL] [Abstract][Full Text] [Related]
9. Modeling of factor XIII activation peptide (28-41) V34L mutant bound to thrombin.
Nair DG; Sunilkumar PN; Sadasivan C
J Biomol Struct Dyn; 2008 Dec; 26(3):387-94. PubMed ID: 18808204
[TBL] [Abstract][Full Text] [Related]
10. Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment.
Jadhav MA; Isetti G; Trumbo TA; Maurer MC
Biochemistry; 2010 Apr; 49(13):2918-24. PubMed ID: 20218626
[TBL] [Abstract][Full Text] [Related]
11. Probing interactions between the coagulants thrombin, Factor XIII, and fibrin(ogen).
Maurer MC; Trumbo TA; Isetti G; Turner BT
Arch Biochem Biophys; 2006 Jan; 445(1):36-45. PubMed ID: 16364233
[TBL] [Abstract][Full Text] [Related]
12. Perturbations in factor XIII resulting from activation and inhibition examined by solution based methods and detected by MALDI-TOF MS.
Sabo TM; Brasher PB; Maurer MC
Biochemistry; 2007 Sep; 46(35):10089-101. PubMed ID: 17691819
[TBL] [Abstract][Full Text] [Related]
13. Mapping of factor XIII solvent accessibility as a function of activation state using chemical modification methods.
Turner BT; Sabo TM; Wilding D; Maurer MC
Biochemistry; 2004 Aug; 43(30):9755-65. PubMed ID: 15274630
[TBL] [Abstract][Full Text] [Related]
14. V34I and V34A substitutions within the factor XIII activation peptide segment (28-41) affect interactions with the thrombin active site.
Trumbo TA; Maurer MC
Thromb Haemost; 2003 Apr; 89(4):647-53. PubMed ID: 12669118
[TBL] [Abstract][Full Text] [Related]
15. Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form.
Schroeder V; Vuissoz JM; Caflisch A; Kohler HP
Thromb Haemost; 2007 Jun; 97(6):890-8. PubMed ID: 17549290
[TBL] [Abstract][Full Text] [Related]
16. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation.
Trumbo TA; Maurer MC
J Biol Chem; 2000 Jul; 275(27):20627-31. PubMed ID: 10801785
[TBL] [Abstract][Full Text] [Related]
17. Effects of Val34Leu and Val35Leu polymorphism on the enzyme activity of the coagulation factor XIII-A.
Lee IH; Chung SI; Lee SY
Exp Mol Med; 2002 Nov; 34(5):385-90. PubMed ID: 12526104
[TBL] [Abstract][Full Text] [Related]
18. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure.
Ariëns RA; Philippou H; Nagaswami C; Weisel JW; Lane DA; Grant PJ
Blood; 2000 Aug; 96(3):988-95. PubMed ID: 10910914
[TBL] [Abstract][Full Text] [Related]
19. Identification of Factor XIII β-Sandwich Residues Mediating Glutamine Substrate Binding and Activation Peptide Cleavage.
Mohammed RDS; Piell KM; Maurer MC
Thromb Haemost; 2024 May; 124(5):408-422. PubMed ID: 38040030
[TBL] [Abstract][Full Text] [Related]
20. Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis.
Duval C; Ali M; Chaudhry WW; Ridger VC; Ariëns RA; Philippou H
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):308-16. PubMed ID: 26743168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
